ctDNA analyses are increasingly considered for cancer
patient management, for prognosis, stratification, treatment response
monitoring and detecting minimal residual disease. Professor Dive will discuss several examples including selection
of Phase I trials with ctDNA.
Circulating tumour cell (CTC) analysis is technically
challenging but can teach us about the biology of dissemination, tumour
evolution and metastasis. Professor Dive will discuss several examples, including the
generation of mouse models of small cell lung cancer derived from patients CTCs.
Multimodal liquid biopsies are likely to be needed for
earlier detection of cancers. Professor Dive will discuss the challenges that lie ahead
focusing on lung cancer.